Novartis Planning to Bring Dispute Over Drug Patent to U.S. Supreme Court
By Scott Kanowsky Investing.com — Novartis AG (SIX:) says it plans to petition the U.S. Supreme Court to uphold the validity of its patent for a dosing regimen of its blockbuster multiple sclerosis drug Gilenya and reverse a federal appeals court decision made earlier this summer. The Swiss pharmaceutical giant vowed to defend its position “vigorously,” but …
Novartis Planning to Bring Dispute Over Drug Patent to U.S. Supreme Court Read More »